Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-05-04
1996-12-31
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 16, 514 18, 514 19, 514 20, 530329, 530330, 530331, 548537, A61K 3804, A61K 3807, C07K 504, C07K 706
Patent
active
055894607
ABSTRACT:
The present invention discloses novel peptides utilized to treat patients suffering from depression. These novel peptides are modifications of the tripeptide hormone MIF, including modification of amino terminus residues, carboxyl terminus residues and internal residues, including addition and substitution of amino acid residues and modification of the peptide bonds and functional side groups of respective amino acid residues. The tri-, tetra-, penta-, and polypeptides of the present invention may be utilized alone or in combination to treat patients suffering from depression.
REFERENCES:
patent: 3708593 (1973-01-01), Plotnikoff et al.
patent: 3795738 (1974-03-01), Plotnikoff et al.
patent: 3821188 (1974-06-01), McKinley et al.
patent: 3931184 (1976-01-01), Lex
patent: 4018912 (1977-04-01), Failli et al.
patent: 4278595 (1981-07-01), Cort
patent: 4610817 (1986-09-01), Albrecht et al.
FEBS Letters, vol. 37, No. 1, issued Nov. 1973, DesLauriers et al, "Intra-Molecular Motion In Peptides . . . ", pp. 27-32.
Heluetica, Chimica Acta, vol. 44, No. 14-15, issued 1961, Jaquenoud et al, "Synthese de la Ileu-oxytocine . . . ", pp. 113-122.
J. Am. Chem. Soc., vol. 82, issued 20 Mar. 1960, Studer et al, "Synthetic Work Related to Arginine-Vasopressin", pp. 1499-1501.
Int. J. Peptide Protein Res., vol. 10, issued 1977, Felix et al, "Synthesis, Biological Activity and Tritiation . . . ", pp. 299-310.
FEBS Letters, vol. 27, No. 2, issued Nov. 1972, Celis et al, "Structure-Activity Studies of MSH-Release-Inhibiting Hormone", pp. 327-330.
Coll. Czech. Chem. Comm., vol. 53, issued 1988, Reissmann et al, "Peptide Inhibitors of the Angiotensin . . . ", pp. 2591-2598.
Celis, et al., 1971, Regulation of Formation and Proposed Structure of the Factor Inhibiting the Release of Melanocyte-Stimulating Hormone, Proc. Natl. Acad. Sci. USA 68 (7): 1428-1433.
Nair, et al., 1971, Isolation Structure of Hypothalamic MSH Release-Inhibiting Hormone, Biochem Biophys. Research Commun., 43 (6): 1376-1381.
Hayashi, et al., 1984, Some Analogs of Tyr-MIF-1 Affect Passive Avoidance Behavior but not Motor Activity in Rats, Pharmacology Biochem & Behavior, 21:809-812.
Kastin, et al., 1984, Tyr-MIF-1 and MIF-1 are Active in the Water Wheel Test for Antidepressant Drugs, Pharmacology Biochem & Behavior, 21:767-771.
Kastin, et al., 1985, Tyr-MIF-1, Identified in Brain Tissue, and Its Analogs are Active in Two Models of Antinociception, Pharamacology Biochem & Behavior, 23:1045-1049.
Banks, et al., 1986, Carrier-Mediated Transport of Enkephalins and N-Tyr-MIF-1 Across Blood Brain Barrier, Am. J. Physiol. (Endorinol. Metab. 14): E477-E482.
Pulvirenti & Kastin, 1988, Blockade of Brain Dopamine Receptors Antagonizes the Anti-Immobility Effect of MIF-1 and Tyr-MIF-1 in Rats, European Journ. of Pharmacology, 151:289-292.
Hayashhi, et al., 1983, Tyr-MIF-1 Affects Passive Avoidance Behavior but not Motor Activity in Rats, Pharm Research Bulletin, 11:659-662.
Abajian Henry B.
Hlavka Joseph J.
Noble John F.
Innapharma, Inc.
Russel Jeffrey E.
LandOfFree
Tri-, tetra-, penta-, and polypeptides and their therapeutic use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tri-, tetra-, penta-, and polypeptides and their therapeutic use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tri-, tetra-, penta-, and polypeptides and their therapeutic use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1142150